Phase II Study of Dasatinib in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer
Phase II Study of Dasatinib in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer
复制标题
DOI：
10.1080/07357907.2016.1253710
复制
发表时间：
2017-01-01
影响因子：
2.4
通讯作者：
Ready, Neal
中科院分区：
文献类型：
--
作者：
Kelley, Michael J.;Jha, Gautam;Ready, Neal
Src通路在大约三分之一的非小细胞肺癌（NSCLC）肿瘤中被激活。达沙替尼具有Src抑制剂活性。我们检查了达沙替尼在37例晚期、既往接受过治疗的NSCLC患者中的活性。在29例接受治疗前活检进行RNA生物标志物分析的患者中，25例接受达沙替尼70 mg每日两次治疗。没有回应。5名患者因毒性而停止治疗。3例患者发生与活检相关的气胸。鉴于缺乏应答，未分析生物标志物。达沙替尼70 mg每日两次在既往接受过治疗的晚期NSCLC NSCLC患者中没有活性，耐受性也不好。
The Src pathway in activated in about one-third of non-small cell lung cancer (NSCLC) tumors. Dasatinib has Src-inhibitor activity. We examined the activity of dasatinib in 37 patients with advanced, previously treated NSCLC. Among the 29 patients who underwent pre-treatment biopsy for RNA biomarker analysis, 25 were treated with dasatinib 70 mg twice daily. There were no responses. Five patients discontinued treatment due to toxicity. Three patients hadminor biopsy-related pneumothoraces. Given the lack of responses, no biomarkers were analyzed. Dasatinib 70 mg twice daily does not have activity nor is it well tolerated in unselected patients with advanced stage, previously treated NSCLC.